NRx Pharmaceuticals, Inc. announced the closing of an underwritten public offering of common stock on June 4, 2026, raising approximately $22.3 million in gross proceeds. The total included the full exercise of the underwriters' option to purchase additional shares. The company intends to use the net proceeds for working capital and general corporate purposes.

Key Details

  • Offering Size: The company sold a total of 6,571,428 shares of common stock, which includes 5,714,286 initial shares and 857,142 shares from the full exercise of the underwriters' option.
  • Pricing & Proceeds: Shares were sold at a public price of $3.50 per share. The offering generated gross proceeds of approximately $22.3 million, with estimated net proceeds of $21.6 million after deducting expenses.
  • Timeline: The underwriting agreement was entered into on June 3, 2026, and the offering closed on June 4, 2026.
  • Underwriters: BTIG, LLC acted as the lead book-running manager for the offering.